Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
Feng Zhou(Soochow University), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yu Cheng(Tianjin University of Technology), Jean J. Zhao(Harvard University), Yixin Yao(The University of Texas MD Anderson Cancer Center), Ying Lü(University of Illinois Urbana-Champaign), Bo Zhu(Hebei Medical University), Lianzhou Wang(Southwest Jiaotong University), Li Zhang(Tianjin Chest Hospital), Ziyi Wang(Shandong Tumor Hospital), Yun Fan(Zhejiang Cancer Hospital), Zhiyong Ma(Ministry of Education of the People's Republic of China), X. Dong(Huazhong University of Science and Technology), Ning Yang(First Affiliated Hospital of Hebei Medical University), Baohui Han(Shanghai Jiao Tong University), Cheng Wang(Peking University), Yunpeng Yang(Sun Yat-sen University)
Cited by 31
Related Papers
Ligand-assisted cation-exchange engineering for high-efficiency colloidal Cs1−xFAxPbI3 quantum dot solar cells with reduced phase segregation
|Nature Energy|2020|585
An Electrochemically Treated BiVO<sub>4</sub> Photoanode for Efficient Photoelectrochemical Water Splitting
|Angewandte Chemie International Edition|2017|527
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380